Osprey Medical, Inc. (ASX: OSP) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Osprey Medical, Inc. Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Osprey Medical, Inc. (ASX: OSP)
    Latest News

    piggy bank next to big red heart representing osprey share price
    Share Market News

    Osprey (ASX:OSP) share price rises on distribution agreement

    The Osprey share price is currently trading higher as the company announced a distribution agreement. We take a closer look…

    Read more »

    Healthcare Shares

    Osprey Medical share price shoots 8% higher after product approval

    The Osprey Medical Inc (ASX: OSP) share price is up by almost 9% today after the company received important CE…

    Read more »

    Share Market News

    Osprey Medical inks new deal with GE Healthcare

    Osprey Medical (ASX: OSP) will partner with US giant GE Healthcare to distribute its life saving medical devices across much…

    Read more »

    a woman
    Share Gainers

    These 3 ASX small caps zoomed higher today

    The Swift Networks Group Ltd (ASX:SW1) share price is one of three in the small cap space zooming higher today.…

    Read more »

    a woman
    ⏸️ Investing

    These 3 small cap shares have surged higher today

    The Supply Network Limited (ASX:SNL) share price is one of three in the small cap space surging higher on Thursday...

    Read more »

    a woman
    ⏸️ Investing

    No profit for Osprey Medical Inc but it's primed for growth

    Growth investors still have their eyes on Osprey Medical Inc (ASX:OSP) despite a profit evading the company for another half.

    Read more »

    a woman
    ⏸️ Investing

    4 ASX stocks sinking today

    The All Ordinaries ends the day flat, but these 4 saw their share prices plunge

    Read more »

    OSP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Mike McCormick Executive DirectorChief Executive OfficerPresident Mar 2010
    Mr McCormick has more than 30 years of experience in the medical device industry and President level experience with both public and private medical device companies. Prior to Osprey Medical, he was President/CEO of Anulex Technologies, Inc., focused on supporting the healing of spinal soft tissues; President of Centerpulse Spine-Tech and was involved in the successful sale of Centerpulse Inc. to Zimmer in 2003 for US$3.2 billion. Mike also spent 10 years in sales and sales leadership positions with Boston Scientific's Cardiovascular Division (SCIMED) and Baxter Healthcare.
    Dr Christopher Dean Nave Non-Executive Director Oct 2005
    Dr Nave is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund. Brandon Capital Partners Pty Limited is the investment manager of various funds which have a substantial security holding in the Company. Dr Nave was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Dr Nave was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. In 2014, Dr Nave was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry. Dr Nave is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology, Azura Ophthalmics and EBR Systems Inc.
    Mr John Erb Non-Executive ChairmanNon-Executive Director Jun 2007
    Mr Erb has over 40 years of experience in the medical device industry. He is currently Chairman of the Board and Chief Executive Officer of CHF Solutions, Inc., a manufacturer of medical devices for the heart failure market. John previously served as Chairman of the Board for Vascular Solutions, Inc., manufacturer of medical devices for the cardiology and interventional radiology markets, which was acquired in 2017 by Teleflex, Inc. for US$1 billion. He has held numerous board positions, including CryoCath Technologies, Inc., acquired by Medtronic for US$350 million in 2008; and SenoRx, Inc., acquired by C.R. Bard for US$250 million in 2010.
    Mr Steven Brandt Non-Executive Director Jul 2021
    Mr Brandt has over 35 years of experience in the healthcare field. Steven holds over 10 years' experience as acting Vice President for Thoratec Corporation where he managed the expansion of global revenue and the eventual acquisition by St. Jude Medical. Steven also held senior positions at CHF Solutions, St. Jude Medical and XRT Corporation (formerly Interventional Innovations). He has served on the board for Vascular Solutions, Inc. and currently sits on the board for Nuwellis, Inc.
    Mr Martin J Emerson Non-Executive Director Aug 2021
    Mr Emerson has over 35 years of experience in the healthcare field. Mr Emerson also has knowledge in market development, geographic expansion and existing market growth. Mr Emerson's experience in healthcare include CEO positions in companies such as American Medical Systems, Galil Medical and his current position as the President and CEO of Monteris Medical. Mr Emerson also has leadership experience in guiding organizations through commercial execution and value creation.
    Mr Brendan Case Company Secretary
    Nancy Ness Chief Financial Officer
    Brendan Case Company Secretary
    Doug Schoenberg VP Marketing Education & Reimbursement
    Melanie Hess VP of Regulatory Affairs Quality Clinical & Compliance
    Vic Fabano VP Operations
    Rod Houfburg VP Research & Development

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    MRCF3 Services (H) Pty Ltd 7,021,450 27.36%
    MRCF3 Services (Sw) Pty Ltd 4,228,500 16.48%
    MRCF3 Services (Hp) Pty Ltd 2,368,912 9.23%
    Citicorp Nominees Pty Limited 716,425 2.79%
    J P Morgan Nominees Australia Pty Limited 569,624 2.22%
    Mr Tianyu Zhu 543,079 2.12%
    Hsbc Custody Nominees (Australia) Limited 407,429 1.59%
    Mr Ligang Zhu 399,939 1.56%
    MRCF3 Services (As) Pty Ltd 343,021 1.34%
    National Nominees Limited 215,536 0.84%
    Dixson Trust Pty Limited 200,000 0.78%
    Paul Mccarthy Nominees Pty Limited <Pma Super Fund A/C> 200,000 0.78%
    Mr Bahram Rezaei 164,000 0.64%
    Bnp Paribas Nominees Pty Ltd 157,677 0.61%
    78 Quarry Road Pty Ltd <David Fergusson Family A/C> 150,000 0.58%
    Havenranch Pty Limited <Racklyeft Ret Fund Account> 137,171 0.53%
    Mr Amirpoya Erbezin Zanjani 136,000 0.53%
    Sacavic Pty Ltd <Morris Super Fund A/C> 120,000 0.47%
    Bbf1 Iif Partnership Lp 108,422 0.42%
    Cappafield Pty Ltd <Cappafield Super A/C> 100,000 0.39%
    Mr Steven Rubic 100,000 0.39%
    N B T Pty Ltd <Astor Super Fund A/C> 97,000 0.38%